Business Wire

Alpine Investors Finalizes Oversubscribed Ninth Fund at Hard Cap of $4.5 Billion in Capital Commitments

12.7.2023 14:30:00 EEST | Business Wire | Press release

Share

Alpine Investors (“Alpine”), a Certified B Corp people-driven private equity firm committed to building enduring software and services companies, announced today the completion of fundraising for Alpine Investors IX (“Fund IX”), reaching the fund’s hard cap of $4.5 billion in limited partner capital commitments.

Fundraising for Fund IX launched with a target of $3.75 billion and was oversubscribed. Fund IX is double the size of Alpine’s previous fund, Alpine Investors VIII, which was similarly oversubscribed and closed at its hard cap of $2.25 billion of limited partner commitments in August 2021.

Fund IX received limited partner commitments from a diversified investor base of returning and new investors from the U.S., Europe, Asia, and the Middle East. Alpine plans to invest the capital for Fund IX in control buyouts of software and services businesses with total enterprise values of up to $1 billion and focus on add-on acquisitions for high-performing platform investments.

“We are thrilled with this outcome, particularly in a very challenging fundraising environment,” said Graham Weaver, Founder and CEO of Alpine Investors. “We started Alpine 22 years ago with the thesis that the secret to building companies was hiring and training world-class leaders. It is incredibly satisfying to think that treating people well and giving them opportunities to be their best selves at work has been the formula for our investing success. We’re extremely grateful to have a wonderful group of like-minded investors and partners who have supported us along the way, and we are excited to continue this amazing journey together with them.”

Alpine has been active in recent years across its software and services specialties through buyouts as well as the launch of several prominent platforms. Notable investments from the last year include:

  • The successful expansion of ASG, Alpine’s software business that buys vertical SaaS companies and builds them into market leaders, with more than 50 acquisitions since inception;
  • The announcement of AlpineX’s professional education vertical, Axcel Learning, and its water services vertical, Axia Water;
  • The formation of predictis, a data-enabled software platform launched in conjunction with the acquisition of AirDNA;
  • The establishment of the Trilon Group, an engineering services platform, with 15 acquisitions including Alta Planning + Design, Inc., a globally-renowned active mobility and sustainability consulting firm;
  • The acquisition of FEV Tutor, a K-12 market leading research and evidence-based online tutoring platform;
  • The acquisition of Medusind, a leading provider of revenue cycle management services to the healthcare industry; and
  • The formation of Ascend, a platform that partners with entrepreneurial CPAs, through its acquisition of Opsahl Dawson.

“We are grateful for the continued partnership from so many long-standing investors in Alpine, and we are excited by the significant presence of new partners across the globe that chose to participate in Fund IX,” said April Smith, Head of Investor Relations and Fundraising, Alpine Investors. “The makeup of Fund IX is the most global of any of our funds to date, demonstrating our expanding reach, and the robust market interest we generated underscores the increasing awareness of our value proposition for investors.”

Founded in 2001, Alpine Investors has over $15 billion in assets under management with more than 20,000 employees within its portfolio companies.1 The firm is known for its PeopleFirst operating philosophy and its executive talent programs, which recruit and develop MBA graduates into CEOs and other executive-level roles. Originating with its CEO-in-Training and CEO-in-Residence programs, Alpine employs over 110 CEOs and executive-level roles within its portfolio companies through these talent programs.

Evercore Inc. served as placement agent for the fund and Kirkland & Ellis served as legal counsel to Alpine.

About Alpine Investors

Alpine Investors is a people-driven private equity firm committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in the software and services industries. Alpine’s PeopleFirst strategy includes a talent program that allows Alpine to bring leadership to situations where additional or new management is needed post-transaction. Alpine has over $15 billion in assets under management as of March 31, 2023 and has three offices in San Francisco, New York, and Salt Lake City.1 For more information, visit www.alpineinvestors.com and https://alpineinvestors.com/terms-conditions/ for full disclaimers including, but not limited to, third-party reviews and Alpine Operations Group.

1 Pro forma for additional Fund IX commitments raised as of June 30, 2023 and fair market value as of March 31, 2023.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Audrey Harris
Head of Marketing
aharris@alpineinvestors.com

Sarah Braunstein
sbraunstein@sloanepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye